Jasper Therapeutics, Inc. (JSPR) has a negative trailing P/E of -0.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -499.18%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -3.5 | 0.00 | 0.82 | 0.00 | - |
| 2020 | -0.5 | 0.00 | -0.49 | 0.00 | - |
| 2021 | -2.9 | 0.03 | 1.29 | 0.00 | - |
| 2022 | -0.5 | 0.01 | 0.49 | 0.00 | - |
| 2023 | -1.3 | 0.03 | 1.05 | 0.00 | - |
| 2024 | -4.4 | 0.21 | 5.06 | 0.00 | - |
| 2025 | -0.5 | 0.02 | 8.45 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $0.00 | $0.00 | $-4.99M | - |
| 2020 | $-114.30 | $0.00 | $-31.67M | - |
| 2021 | $-26.90 | $0.00 | $-30.64M | - |
| 2022 | $-10.30 | $0.00 | $-37.69M | - |
| 2023 | $-6.18 | $0.00 | $-64.47M | - |
| 2024 | $-4.89 | $0.00 | $-71.27M | - |
| 2025 | $-3.95 | $0.00 | $-75.8M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.34 | $-2.70 – $-2.15 | $1.11M | $1.11M – $1.11M | 4 |
| 2027 | $-1.78 | $-2.49 – $-1.06 | $173.8K | $173.8K – $173.8K | 3 |
| 2028 | $-2.02 | $-4.53 – $-0.32 | $33.88M | $33.88M – $33.88M | 4 |
| 2029 | $-0.32 | $-0.32 – $-0.32 | $75M | $75M – $75M | 2 |
| 2030 | $-1.01 | $-1.01 – $-1.01 | $25.28M | $25.28M – $25.28M | 2 |
